Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Aug 15, 2016	Evoke Pharma Reports Second Quarter 2016 Results SOLANA BEACH, Calif., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal diseases, today announced its financial results for the second quarter ended June 30, 2016.	View HTML Evoke Pharma Reports Second Quarter 2016 Results 27.2 KB
Toggle Summary Aug 10, 2016	Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results SOLANA BEACH, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter 2016 on Monday, August 15, 2016,	View HTML Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2016 Financial Results 12.1 KB
Toggle Summary Aug 08, 2016	Evoke Pharma Completes Credit Facility Repayment SOLANA BEACH, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced it has paid all of the outstanding amounts of indebtedness under its loan and	View HTML Evoke Pharma Completes Credit Facility Repayment 14.2 KB
Toggle Summary Jul 29, 2016	Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market SOLANA BEACH, Calif., July 29, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) ("Evoke Pharma" or "the Company"), today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10	View HTML Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market 15.9 KB
Toggle Summary Jul 26, 2016	Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 SOLANA BEACH, Calif., July 26, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the US Food and Drug Administration (FDA) has conditionally accepted the proprietary brand	View HTML Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001 14.7 KB
Toggle Summary Jul 20, 2016	Evoke Pharma Announces $4.5 Million At-The-Market Offering SOLANA BEACH, Calif., July 20, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK) (the "Company"), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for an	View HTML Evoke Pharma Announces $4.5 Million At-The-Market Offering 15.4 KB
Toggle Summary Jul 18, 2016	Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial SOLANA BEACH, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic	View HTML Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial 18.1 KB
Toggle Summary Jul 07, 2016	Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement SOLANA BEACH, Calif. , July 07, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has entered into a master service agreement with inVentiv Commercial Services LLC ("inVentiv") in connection with Evoke's preparation for commercial activities for EVK-001, its lead	View HTML Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement 15.9 KB
Toggle Summary Jun 01, 2016	Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 205 subjects complete the study	View HTML Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 16.9 KB
Toggle Summary May 24, 2016	Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 Further Safety of EVK-001 Demonstrated with TQT Results	View HTML Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016 16.5 KB